Supriya Lifescience Limited
Supriya Lifescience Limited Fundamental Analysis
Supriya Lifescience Limited (SUPRIYA.NS) shows strong financial fundamentals with a PE ratio of 26.60, profit margin of 25.19%, and ROE of 18.61%. The company generates $7.4B in annual revenue with strong year-over-year growth of 22.12%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 86.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze SUPRIYA.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentSUPRIYA.NS demonstrates superior asset utilization.
Valuation Score
WeakSUPRIYA.NS trades at a premium to fair value.
Growth Score
ExcellentSUPRIYA.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentSUPRIYA.NS maintains a strong and stable balance sheet.
Profitability Score
ExcellentSUPRIYA.NS achieves industry-leading margins.
Key Financial Metrics
Is SUPRIYA.NS Expensive or Cheap?
P/E Ratio
SUPRIYA.NS trades at 26.60 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, SUPRIYA.NS's PEG of 17.23 indicates potential overvaluation.
Price to Book
The market values Supriya Lifescience Limited at 4.56 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 18.29 times EBITDA. This signals the market has high growth expectations.
How Well Does SUPRIYA.NS Make Money?
Net Profit Margin
For every $100 in sales, Supriya Lifescience Limited keeps $25.19 as profit after all expenses.
Operating Margin
Core operations generate 32.36 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.61 in profit for every $100 of shareholder equity.
ROA
Supriya Lifescience Limited generates $15.40 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Supriya Lifescience Limited generates limited operating cash flow of $555.46M, signaling weaker underlying cash strength.
Free Cash Flow
Supriya Lifescience Limited generates weak or negative free cash flow of $133.11M, restricting financial flexibility.
FCF Per Share
Each share generates $1.65 in free cash annually.
FCF Yield
SUPRIYA.NS converts 0.27% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
26.60
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
17.23
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.56
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.70
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.005
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.09
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.19
vs 25 benchmark
ROA
Return on assets percentage
0.15
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How SUPRIYA.NS Stacks Against Its Sector Peers
| Metric | SUPRIYA.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 26.60 | 28.45 | Neutral |
| ROE | 18.61% | 763.00% | Weak |
| Net Margin | 25.19% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 6.09 | 2795.60 | Strong Liquidity |
| ROA | 15.40% | -16588.00% (disorted) | Strong |
SUPRIYA.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Supriya Lifescience Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-29.07%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-18.73%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-52.81%
Industry Style: Defensive, Growth, Innovation
Declining